IS4378A - Aðferðir til að kalla fram T-eitilfrumu þol í ígræddum vef eða líffæri - Google Patents

Aðferðir til að kalla fram T-eitilfrumu þol í ígræddum vef eða líffæri

Info

Publication number
IS4378A
IS4378A IS4378A IS4378A IS4378A IS 4378 A IS4378 A IS 4378A IS 4378 A IS4378 A IS 4378A IS 4378 A IS4378 A IS 4378A IS 4378 A IS4378 A IS 4378A
Authority
IS
Iceland
Prior art keywords
organs
inducing
methods
implanted tissue
lymphocyte tolerance
Prior art date
Application number
IS4378A
Other languages
English (en)
Other versions
IS2118B (is
Inventor
J. Noelle Randolph
H. Durie Fiona
C. Parker David
C. Appel Michael
E. Phillips Nancy
P. Mordes John
L. Grenier Dale
A. Rossini Aldo
Original Assignee
Trustees Of Dartmouth College
University Of Massachusetts Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trustees Of Dartmouth College, University Of Massachusetts Medical Center filed Critical Trustees Of Dartmouth College
Publication of IS4378A publication Critical patent/IS4378A/is
Publication of IS2118B publication Critical patent/IS2118B/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46434—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
IS4378A 1994-04-25 1996-10-22 Aðferðir til að kalla fram T-eitilfrumu þol í ígræddum vef eða líffæri IS2118B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/234,987 US5683693A (en) 1994-04-25 1994-04-25 Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
PCT/US1995/004832 WO1995028957A2 (en) 1994-04-25 1995-04-25 Methods for inducing t cell tolerance to a tissue or organ graft

Publications (2)

Publication Number Publication Date
IS4378A true IS4378A (is) 1996-10-22
IS2118B IS2118B (is) 2006-06-15

Family

ID=22883593

Family Applications (1)

Application Number Title Priority Date Filing Date
IS4378A IS2118B (is) 1994-04-25 1996-10-22 Aðferðir til að kalla fram T-eitilfrumu þol í ígræddum vef eða líffæri

Country Status (34)

Country Link
US (4) US5683693A (is)
EP (2) EP1530973A3 (is)
JP (1) JP2974415B2 (is)
KR (1) KR100468330B1 (is)
CN (1) CN1134266C (is)
AP (1) AP764A (is)
AT (1) ATE288281T1 (is)
AU (1) AU710925B2 (is)
BG (1) BG62121B1 (is)
BR (1) BR9507509A (is)
CA (1) CA2188672A1 (is)
CZ (1) CZ291266B6 (is)
DE (1) DE69533984T2 (is)
DK (1) DK0757557T3 (is)
EE (1) EE03516B1 (is)
ES (1) ES2237757T3 (is)
FI (1) FI118792B (is)
GE (1) GEP20022648B (is)
HU (1) HU221752B1 (is)
IS (1) IS2118B (is)
LT (1) LT4309B (is)
LV (1) LV11785B (is)
MD (1) MD1444B2 (is)
NO (2) NO319787B1 (is)
NZ (1) NZ284905A (is)
OA (1) OA10591A (is)
PL (1) PL180031B1 (is)
PT (1) PT757557E (is)
RO (1) RO114743B1 (is)
RU (1) RU2169009C2 (is)
SI (1) SI9520057A (is)
SK (1) SK136996A3 (is)
UA (1) UA44892C2 (is)
WO (1) WO1995028957A2 (is)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474771A (en) 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US7070777B1 (en) * 1991-11-15 2006-07-04 The Trustees Of Columbia University In The City Of New York Method for inhibiting inflammation with an antibody that binds the 5C8 protein
US6472510B1 (en) 1992-02-14 2002-10-29 Bristol-Myers Squibb Company CD40 receptor ligands
CN100341896C (zh) * 1993-09-02 2007-10-10 达特茅斯学院理事 抗gp39抗体及其应用
ZA946765B (en) * 1993-09-02 1996-02-15 Dartmouth College Methods of prolonged suppression of humoral immunity
US5683693A (en) * 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
US5876950A (en) * 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
US6440418B1 (en) 1995-11-07 2002-08-27 Idec Pharmaceuticals Corporation Methods of treating autoimmune diseases with gp39-specific antibodies
US6001358A (en) 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
US6340459B1 (en) 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
IL125928A (en) * 1996-03-20 2002-11-10 Bristol Myers Squibb Co The use of soluble ligands that react with CTLA4, B7, CD40, gp39 and / or CD28 for the preparation of pharmaceutical preparations
BR9807471A (pt) * 1997-01-10 2000-03-21 Biogen Inc Uso do composto anti-cd40l
ATE339966T1 (de) * 1997-06-20 2006-10-15 Biogen Idec Inc Cd154-blockadetherapie der pankreasinselzelltransplantation bei primaten
EP1754490A3 (en) * 1997-06-20 2010-01-20 Biogen Idec MA Inc. CD 154 blockage therapy for pancreatic islet tissue transplantation in primates
US20050031611A1 (en) * 1998-05-08 2005-02-10 Beth Israel Deaconess Medical Center Transplant tolerance by costimulation blockade and T-cell activation-induced apoptosis
WO2000006178A1 (en) * 1998-07-30 2000-02-10 Regents Of The University Of Minnesota EX VIVO TREATMENT OF ALLOGENEIC AND XENOGENEIC T-CELLS WITH gp39 ANTAGONISTS
US20020199218A1 (en) * 1999-08-19 2002-12-26 Daphne Goring Proline-rich extensin-like receptor kinases
RU2162297C1 (ru) * 1999-11-25 2001-01-27 Камакин Владислав Владимирович Способ индивидуального подбора оптимального питания человека
WO2001079555A2 (en) 2000-04-14 2001-10-25 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
AU2001261585B2 (en) 2000-05-12 2006-08-31 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for achieving immune suppression
EP1289554A4 (en) * 2000-06-02 2004-05-26 Univ Minnesota IMMUNOTHERAPEUTIC PROCESS FOR PREVENTING REJECTION OF ISLAND CELLS
EP1299542A2 (en) * 2000-06-06 2003-04-09 Idec Pharmaceuticals Corporation Non-agonistic antibodies to human gp39, compositions containing, and therapeutic use thereof
DE60135029D1 (de) 2000-07-03 2008-09-04 Bristol Myers Squibb Co Verwendung von löslichen ctla4-mutanten zur behandlung von rheumatoider arthritis
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
CA2364983A1 (en) * 2000-12-13 2002-06-13 John R. Coleman Nucleic acid molecules and polypeptides for catabolism of abscisic acid
WO2002078743A1 (en) * 2001-02-16 2002-10-10 University Of Rochester Compositions and methods for reducing tranfusion reactions
US7556807B2 (en) 2001-02-20 2009-07-07 Kane Biotech, Inc. Signal peptides, nucleic acid molecules and methods for treatment of caries
US7597895B2 (en) * 2001-02-20 2009-10-06 The Governing Council Of The University Of Toronto Signal peptides, nucleic acid molecules and methods for treatment of caries
DK1397153T3 (da) 2001-05-23 2008-05-26 Bristol Myers Squibb Co Fremgangsmåde til beskyttelse af allogent ö-celle-transplantat ved anvendelse af oplöselige CTLA4-mutantmolekyler
US7498171B2 (en) 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
JP2006512895A (ja) * 2002-06-28 2006-04-20 ドマンティス リミテッド リガンド
WO2005006949A2 (en) * 2003-07-07 2005-01-27 Wagner David H Methods for predicting development of auto-immune diseases and treatment of same
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
EP1795587A1 (en) * 2005-12-07 2007-06-13 Schuler, Gerold, Prof. Dr. Method for the direct culture of dendritic cells without a preceding centrifugation step
ES2530637T3 (es) * 2006-03-02 2015-03-04 Alexion Pharma Inc Prolongación de la supervivencia de un aloinjerto por inhibición de la actividad del complemento
FR2934140B1 (fr) * 2008-07-25 2010-09-03 Seb Sa Couvercle d'appareil electromenager de cuisson comportant un sous-ensemble de filtration
WO2010148501A1 (en) 2009-06-26 2010-12-29 Soricimed Biopharma Inc. Soricidin derived peptides and methods for the detection of trpv-6 cancers and drug delivery
WO2013013708A1 (en) 2011-07-26 2013-01-31 Fundació Institut D'investigació Biomèdica De Bellvitge Treatment of acute rejection in renal transplant
KR102656470B1 (ko) 2014-12-10 2024-04-09 리전츠 오브 더 유니버스티 오브 미네소타 질환을 치료하기 위한 유전적으로 변형된 세포, 조직 및 장기
RU2580640C1 (ru) * 2014-12-25 2016-04-10 Федеральное государственное бюджетное учреждение "Федеральный научный центр трансплантологии и искусственных органов имени академика В.И. Шумакова" Министерства здравоохранения Российской Федерации Способ профилактики гуморального отторжения при аво-несовместимой трансплантации печени детям раннего возраста
RU2688172C1 (ru) * 2018-04-05 2019-05-20 Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) Способ профилактики отторжения трансплантата трупной почки

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0585963A1 (en) * 1989-05-23 1994-03-09 Otsuka Pharmaceutical Co., Ltd. Monoclonal antibodies to CMP-170 antigen on activated endothelial cells
US5690933A (en) * 1989-05-31 1997-11-25 Glaxo Wellcome Inc. Monoclonal antibodies for inducing tolerance
AU661360B2 (en) * 1991-10-25 1995-07-20 Immunex Corporation Novel cytokine
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
IL104684A0 (en) * 1992-02-14 1993-06-10 Bristol Myers Squibb Co The cd40cr receptor and ligands therefor
WO1994004570A1 (en) * 1992-08-21 1994-03-03 Schering Corporation Cd40 ligand, anti cd40 antibodies, and soluble cd40
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
US5597563A (en) * 1992-09-04 1997-01-28 Beschorner; William E. Method induction of antigen-specific immune tolerance
CA2109398A1 (en) * 1992-10-30 1994-05-01 Alejandro A. Aruffo Extracellular matrix receptor ligands that modulate leukocyte function
CN100341896C (zh) * 1993-09-02 2007-10-10 达特茅斯学院理事 抗gp39抗体及其应用
ZA946765B (en) * 1993-09-02 1996-02-15 Dartmouth College Methods of prolonged suppression of humoral immunity
US5869049A (en) * 1993-09-02 1999-02-09 Trustees Of Dartmouth College Methods of inducing T cell unresponsiveness to bone marrow with gp39 antagonists
US5683693A (en) 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40

Also Published As

Publication number Publication date
BG62121B1 (bg) 1999-03-31
SI9520057A (sl) 1998-06-30
RO114743B1 (ro) 1999-07-30
KR100468330B1 (ko) 2005-12-30
ES2237757T3 (es) 2005-08-01
US5683693A (en) 1997-11-04
AU710925B2 (en) 1999-09-30
FI964272A (fi) 1996-12-19
BR9507509A (pt) 1997-02-02
DK0757557T3 (da) 2005-05-23
WO1995028957A2 (en) 1995-11-02
IS2118B (is) 2006-06-15
JP2974415B2 (ja) 1999-11-10
MD970009A (en) 1999-01-31
US6375950B1 (en) 2002-04-23
EP0757557A1 (en) 1997-02-12
CZ312596A3 (en) 1997-03-12
RU2169009C2 (ru) 2001-06-20
SK136996A3 (en) 1999-01-11
EP1530973A2 (en) 2005-05-18
DE69533984T2 (de) 2006-04-27
PL180031B1 (pl) 2000-12-29
EP1530973A3 (en) 2006-12-27
CZ291266B6 (cs) 2003-01-15
NZ284905A (en) 2004-10-29
EE03516B1 (et) 2001-10-15
UA44892C2 (uk) 2002-03-15
AU2358595A (en) 1995-11-16
NO20051182L (no) 1996-12-23
FI118792B (fi) 2008-03-31
AP9600906A0 (en) 1997-01-31
US7501124B2 (en) 2009-03-10
CA2188672A1 (en) 1995-11-02
DE69533984D1 (de) 2005-03-10
AP764A (en) 1999-09-16
WO1995028957A3 (en) 1995-11-23
LV11785A (lv) 1997-06-20
LT4309B (lt) 1998-03-25
LV11785B (en) 1998-02-20
LT96165A (en) 1997-11-25
EE9600162A (et) 1997-06-16
CN1150760A (zh) 1997-05-28
EP0757557B1 (en) 2005-02-02
HU221752B1 (hu) 2002-12-28
FI964272A0 (fi) 1996-10-23
JPH09512271A (ja) 1997-12-09
US20050152897A1 (en) 2005-07-14
NO319787B1 (no) 2005-09-12
MD1444B2 (ro) 2000-04-30
ATE288281T1 (de) 2005-02-15
CN1134266C (zh) 2004-01-14
PL317022A1 (en) 1997-03-03
US5902585A (en) 1999-05-11
BG100991A (en) 1998-01-30
NO964440D0 (no) 1996-10-18
OA10591A (en) 2002-07-15
GEP20022648B (en) 2002-03-25
NO964440L (no) 1996-12-23
PT757557E (pt) 2005-05-31
HU9602924D0 (en) 1996-12-30
HUT76091A (en) 1997-06-30

Similar Documents

Publication Publication Date Title
IS4378A (is) Aðferðir til að kalla fram T-eitilfrumu þol í ígræddum vef eða líffæri
DE69500014D1 (de) Widerlager zur Klammerung von weichem Gewebe
DE69635311D1 (de) Elektrochirugische gewebeentfernung
FR2722980B1 (fr) Implant vertebral inter-epineux
DE9403341U1 (de) Künstlicher Fuß
DE69608562T2 (de) Chirurgisches maschengewebe
DE59710630D1 (de) Retina-implantat
DE69629360D1 (de) Chirurgische prothese
DE9403231U1 (de) Chirurgisches Implantat
DE69507480T2 (de) Wirbelkörperimplantat
ID15858A (id) Turunan triazol yang berguna dalam terapi
DE59507573D1 (de) Implantat
DE69530843D1 (de) Vorrichtungen zum präparieren von knochen/gewebe
FR2723691B1 (fr) Implant intra-oculaire
DE9402695U1 (de) Implantat
DE69526389T2 (de) Offenes gewebe-implantat-system
DE29511146U1 (de) Wirbelsäulenimplantat
DE69501945D1 (de) Konditionierung von geweben
DE69702125T2 (de) Implantat zum einzementieren in knochen
ITMI950222A0 (it) Tessuto
DE29504057U1 (de) Fersenspornkissen
DE29613701U1 (de) Chirurgisches Implantationsinstrument
DE29503674U1 (de) Zerlegbarer Patienten-Lothublifter in Leichtausführung
DE29519142U1 (de) Fixationsimplantat
FI1449U1 (fi) Anatomisk omformbar kudde